Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Más filtros











Intervalo de año de publicación
1.
J Nurs Educ ; 63(8): 533-539, 2024 08.
Artículo en Inglés | MEDLINE | ID: mdl-39120506

RESUMEN

BACKGROUND: Nursing students are prone to academic burnout (AB) as the result of frequent exposure to stressful situations. AB is associated with physical and mental health problems; thus, identifying the burden of AB is crucial for prevention. This review sought to estimate the global prevalence of AB among nursing students. METHOD: PubMed, Web of Science, EBSCO, SciELO, CUIDEN, LILACS, and BASE databases were searched. The prevalence of AB was estimated using random effects meta-analysis. RESULTS: A total of 34 studies (n = 9,554 students) were included. The pooled prevalence of AB was 35% (95% CI [24%, 47%]; n = 23 studies), with the highest prevalence (58%) observed in Asia. The pooled prevalence of high emotional exhaustion, high depersonalization, and low personal accomplishment was 40%, 23%, and 30%, respectively. CONCLUSION: AB is more common than previously estimated among nursing students. Academic institutions should consider AB in their core curriculum. [J Nurs Educ. 2024;63(8):533-539.].


Asunto(s)
Agotamiento Profesional , Estudiantes de Enfermería , Humanos , Estudiantes de Enfermería/psicología , Estudiantes de Enfermería/estadística & datos numéricos , Agotamiento Profesional/epidemiología , Agotamiento Profesional/psicología , Prevalencia
2.
Viruses ; 16(6)2024 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-38932122

RESUMEN

In this study, we pioneered an alternative technology for manufacturing subunit influenza hemagglutinin (HA)-based vaccines. This innovative method involves harnessing the pupae of the Lepidoptera Trichoplusia ni (T. ni) as natural biofactories in combination with baculovirus vectors (using CrisBio® technology). We engineered recombinant baculoviruses encoding two versions of the HA protein (trimeric or monomeric) derived from a pandemic avian H7N1 virus A strain (A/chicken/Italy/5093/99). These were then used to infect T. ni pupae, resulting in the production of the desired recombinant antigens. The obtained HA proteins were purified using affinity chromatography, consistently yielding approximately 75 mg/L of insect extract. The vaccine antigen effectively immunized poultry, which were subsequently challenged with a virulent H7N1 avian influenza virus. Following infection, all vaccinated animals survived without displaying any clinical symptoms, while none of the mock-vaccinated control animals survived. The CrisBio®-derived antigens induced high titers of HA-specific antibodies in the vaccinated poultry, demonstrating hemagglutination inhibition activity against avian H7N1 and human H7N9 viruses. These results suggest that the CrisBio® technology platform has the potential to address major industry challenges associated with producing recombinant influenza subunit vaccines, such as enhancing production yields, scalability, and the speed of development, facilitating the global deployment of highly effective influenza vaccines.


Asunto(s)
Anticuerpos Antivirales , Pollos , Glicoproteínas Hemaglutininas del Virus de la Influenza , Vacunas contra la Influenza , Gripe Aviar , Pupa , Vacunas de Subunidad , Animales , Vacunas contra la Influenza/inmunología , Vacunas contra la Influenza/genética , Vacunas contra la Influenza/administración & dosificación , Pupa/inmunología , Gripe Aviar/prevención & control , Gripe Aviar/inmunología , Vacunas de Subunidad/inmunología , Vacunas de Subunidad/genética , Glicoproteínas Hemaglutininas del Virus de la Influenza/inmunología , Glicoproteínas Hemaglutininas del Virus de la Influenza/genética , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/sangre , Subtipo H7N1 del Virus de la Influenza A/inmunología , Subtipo H7N1 del Virus de la Influenza A/genética , Baculoviridae/genética , Subtipo H7N9 del Virus de la Influenza A/inmunología , Subtipo H7N9 del Virus de la Influenza A/genética , Humanos , Desarrollo de Vacunas , Mariposas Nocturnas/inmunología , Pandemias/prevención & control
3.
PLoS One ; 10(10): e0140039, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26458221

RESUMEN

Vaccines based on virus-like particles (VLPs) have proven effective in humans and animals. In this regard, the baculovirus expression vector system (BEVS) is one of the technologies of choice to generate such highly immunogenic vaccines. The extended use of these vaccines for human and animal populations is constrained because of high production costs, therefore a significant improvement in productivity is crucial to ensure their commercial viability. Here we describe the use of the previously described baculovirus expression cassette, called TB, to model the production of two VLP-forming vaccine antigens in insect cells. Capsid proteins from porcine circovirus type 2 (PCV2 Cap) and from the calicivirus that causes rabbit hemorrhagic disease (RHDV VP60) were expressed in insect cells using baculoviruses genetically engineered with the TB expression cassette. Productivity was compared to that obtained using standard counterpart vectors expressing the same proteins under the control of the polyhedrin promoter. Our results demonstrate that the use of the TB expression cassette increased the production yields of these vaccine antigens by around 300% with respect to the standard vectors. The recombinant proteins produced by TB-modified vectors were fully functional, forming VLPs identical in size and shape to those generated by the standard baculoviruses, as determined by electron microscopy analysis. The use of the TB expression cassette implies a simple modification of the baculovirus vectors that significantly improves the cost efficiency of VLP-based vaccine production, thereby facilitating the commercial viability and broad application of these vaccines for human and animal health.


Asunto(s)
Baculoviridae/genética , Baculoviridae/inmunología , Vectores Genéticos/biosíntesis , Vacunas de Partículas Similares a Virus/biosíntesis , Animales , Línea Celular , Análisis Costo-Beneficio , Vectores Genéticos/inmunología , Proteínas de Insectos/genética , Proteínas de Insectos/metabolismo , Regiones Promotoras Genéticas , Conejos , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/genética , Spodoptera/citología , Porcinos , Vacunas de Partículas Similares a Virus/genética
4.
Med. oral patol. oral cir. bucal (Internet) ; 19(2): e157-e162, mar. 2014. ilus, mapas
Artículo en Inglés | IBECS | ID: ibc-121355

RESUMEN

OBJECTIVES: To evaluate the anti-inflammatory and analgesic effect of Bromelain (pineapple extract) administered orally in the postoperative after extraction of impacted lower molars. Study DESIGN: This is a prospective, placebo-controlled, unicentric, double-blind study; the sample size was 34 patients. The pre and postoperative outcomes, evaluated on the third (D3) and eighth day (D8), included inflamtion, pain and oral aperture, as well as the need for analgesics. One group received Bromelain 150mg per day for three days and 100mg on days 4 to 7. The other group received placebo in the same dosage. All outcomes werrecorded quantitatively and analyzed with the Mann-Whitney U test for independent samples. RESULTS: Although there were no statistically significant differences between the treatment groups, a trend towards less inflammation and improved oral aperture was observed in the group that received Bromelain, compared to the group that received placebo. This trend can be attributed completely to random reasons, since there is no statistical difference in the results. CONCLUSIONS: Further studies are necessary to analyze different administration patterns and doses of Bromelain for the use in the postoperative of impacted third molars


Asunto(s)
Humanos , Dolor Postoperatorio/tratamiento farmacológico , Tercer Molar/cirugía , Bromelaínas/farmacocinética , Método Doble Ciego , Analgésicos/uso terapéutico , Extracción Dental
7.
PLoS One ; 7(12): e51181, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23236448

RESUMEN

Parasitic diseases plague billions of people among the poorest, killing millions annually, and causing additional millions of disability-adjusted life years lost. Leishmaniases affect more than 12 million people, with over 350 million people at risk. There is an urgent need for efficacious and cheap vaccines and treatments against visceral leishmaniasis (VL), its most severe form. Several vaccination strategies have been proposed but to date no head-to-head comparison was undertaken to assess which is the best in a clinical model of the disease. We simultaneously assayed three vaccination strategies against VL in the hamster model, using KMPII, TRYP, LACK, and PAPLE22 vaccine candidate antigens. Four groups of hamsters were immunized using the following approaches: 1) raw extracts of baculovirus-infected Trichoplusia ni larvae expressing individually one of the four recombinant proteins (PROT); 2) naked pVAX1 plasmids carrying the four genes individually (DNA); 3) a heterologous prime-boost (HPB) strategy involving DNA followed by PROT (DNA-PROT); and 4) a Control including empty pVAX1 plasmid followed by raw extract of wild-type baculovirus-infected T. ni larvae. Hamsters were challenged with L. infantum promastigotes and maintained for 20 weeks. While PROT vaccine was not protective, DNA vaccination achieved protection in spleen. Only DNA-PROT vaccination induced significant NO production by macrophages, accompanied by a significant parasitological protection in spleen and blood. Thus, the DNA-PROT strategy elicits strong immune responses and high parasitological protection in the clinical model of VL, better than its corresponding naked DNA or protein versions. Furthermore, we show that naked DNA coupled with raw recombinant proteins produced in insect larvae biofactories -the cheapest way of producing DNA-PROT vaccines- is a practical and cost-effective way for potential "off the shelf" supplying vaccines at very low prices for the protection against leishmaniases, and possibly against other parasitic diseases affecting the poorest of the poor.


Asunto(s)
ADN/inmunología , Leishmania/inmunología , Leishmaniasis/prevención & control , Proteínas Recombinantes/inmunología , Vacunación/métodos , Animales , Antígenos Virales/inmunología , Cricetinae , Humanos , Leishmaniasis/patología , Mariposas Nocturnas/metabolismo , Plásmidos/genética , Estadísticas no Paramétricas
8.
J Med Chem ; 54(8): 2627-45, 2011 Apr 28.
Artículo en Inglés | MEDLINE | ID: mdl-21417225

RESUMEN

A molecular library of quaternary ammonium salts (QASs), mainly composed of symmetrical bis-quaternary heterocyclic bromides exhibiting choline kinase (ChoK) inhibitory activity, were evaluated for their ability to inhibit acetyl- and butyrylcholinesterase (AChE and BChE, respectively). The molecular framework of QASs consisted of two positively charged heteroaromatic (pyridinium or quinolinium) or sterically hindered aliphatic (quinuclidinium) nitrogen rings kept at an appropriate distance by lipophilic rigid or semirigid linkers. Many homodimeric QASs showed AChE and BChE inhibitory potency in the nanomolar range along with a low enzymatic selectivity. Computational studies on AChE, BChE, and ChoK allowed identification of the key molecular determinants for high affinity and selectivity over either one of the three enzymes and guided the design of a hybrid bis-QAS (56) exhibiting the highest AChE affinity (IC(50) = 15 nM) and selectivity over BChE and ChoK (SI = 50 and 562, respectively) and a promising pharmacological potential in myasthenia gravis and neuromuscular blockade.


Asunto(s)
Acetilcolinesterasa/efectos adversos , Butirilcolinesterasa/efectos adversos , Inhibidores de la Colinesterasa/farmacología , Compuestos Heterocíclicos/farmacología , Compuestos de Amonio Cuaternario/farmacología , Cationes , Inhibidores de la Colinesterasa/química , Dimerización , Compuestos Heterocíclicos/química , Modelos Moleculares , Compuestos de Amonio Cuaternario/química
9.
Am J Trop Med Hyg ; 83(6): 1287-94, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21118936

RESUMEN

Leishmania infantum causes visceral leishmaniasis, a severe zoonotic and systemic disease that is fatal if left untreated. Identification of the antigens involved in Leishmania-specific protective immune response is a research priority for the development of effective control measures. For this purpose, we evaluated, in 27 dogs from an enzootic zone, specific humoral and cellular immune response by delayed-type hypersensitivity (DTH) skin test both against total L. infantum antigen and the raw Trichoplusia ni insect-derived kinetoplastid membrane protein-11 (rKMPII), tryparedoxin peroxidase (rTRYP), Leishmania homologue of receptors for activated C kinase (rLACK), and 22-kDa potentially aggravating protein of Leishmania (rpapLe22) antigens from this parasite. rTRYP induced the highest number of positive DTH responses (55% of leishmanin skin test [LST]-positive dogs), showing that TRYP antigen is an important T cell immunogen, and it could be a promising vaccine candidate against this disease. When TRYP-DTH and KMPII-DTH tests were evaluated in parallel, 82% of LST-positive dogs were detected, suggesting that both antigens could be considered as components of a standardized DTH immunodiagnostic tool for dogs.


Asunto(s)
Antígenos de Protozoos/inmunología , Leishmania infantum/metabolismo , Leishmaniasis Visceral/veterinaria , Proteínas de la Membrana/inmunología , Proteínas Protozoarias/inmunología , Animales , Antígenos de Protozoos/metabolismo , Perros , Ensayo de Inmunoadsorción Enzimática , Femenino , Hipersensibilidad Tardía , Inmunidad Humoral , Masculino , Proteínas de la Membrana/metabolismo , Proteínas Protozoarias/metabolismo
10.
Expert Opin Drug Discov ; 3(10): 1223-35, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23489079

RESUMEN

BACKGROUND: (RS)-1-{[3-(2-Hydroxyethoxy)-1-isopropoxy]propyl}-5-fluorouracil proved to be a good differentiating agent against rhabdomyosarcoma cells. OBJECTIVE: As lipophilicity is known to affect the anticancer activity, the synthesis of a wide range of 5-fluorouracil derivatives linked to benzo-fused seven-membered rings was undertaken. METHODS: The decision was then made to change 5-fluorouracil for uracil, with the prospect of finding an antiproliferative agent endowed with a new mechanism of action. Later on, pyrimidines were substituted for purines. Completing a structure-activity relationship study, a series of isosteric seven-membered derivatives were prepared. RESULTS/CONCLUSION: Finally, molecules were designed in which both structural entities (such as the benzoheterocycle and the purine) were linked through a strong C-C bond. The anticancer activity for the most active compounds was correlated with their capability to induce apoptosis.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA